Hospital de Sabadell

Sabadell, Barcelona 08208

0 studies enrolling now · 2 studies all time

What they study most

Adjuvant, EGFR, Early Stage Lung Cancer, Exon 20, Liver Stiffness, Lung Cancer, NSCLC, Stage IB-IIIA, Post-surgical, Primary Biliary Cholangitis, Uncommon EGFR Mutations

Studies at this site

• A Study to Assess the Efficacy and Safety of Zipalertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB-IIIA NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection — Running, not enrolling
• A Trial of Setanaxib in Patients With Primary Biliary Cholangitis (PBC) and Liver Stiffness — Completed